

### EMA Quality Innovation Group (QIG):

# Two years experience in regulatory support of Innovation in pharmaceutical manufacturing

ISG, 30.06.2025

Evdokia Korakianiti, PhD Head of Quality and Safety Dpt, Human Medicines Div, EMA



# QIG: EU catalyst for advanced manufacturing

Training, quidance

**Assessment support** 

technology novelty

development throughout

tailored to

**Support from** 

lifecycle





European medicines regulatory network

Rapporteurs and Assessment Teams

Predictable reg framework Support EU innovation efforts

Support

International regulatory convergence

QIG

Quality Innovation Group
8 Core experts
(Chemical, Biological,

ATMP & GMP)

+ ad hoc experts





**Academic expertise** 

**Research projects** 

Links







Point of entry to EMRN Informed open discussions




EU Innovation network, ITF, National IOs

Hoefnagel, QIG, DIA-Europe, March 2025

# Quality Innovation Group -Activities





# QIG priority topics discussed at Listen & Learn Focus Groups 📀



Decentralised manufacturing

Continuous manufacturing (Biologicals or End-to-End) Digitalisation and Automation of manufacturing and control

What to document and How?

1<sup>st</sup> LLFG (13 March 2023)

2<sup>nd</sup> LLFG (12 October 2023)

**Actual examples, Tangible presentations** 

Lifecycle, PQS or dossier, level of detail

Close to Patient

POD, QP

Process models 3rd LLFG (4 June 2024)

Platform technologies 4th LLFG (Q4 2024) Personalised Medicines 5th LLFG (Q2 2025)

Definition, End-to-End

Meeting reports incl. challenges, possible solutions and concrete actions that OIG will take to address the challenges

## Guidance and product support



 Helping avoid shortages: X-ray sterilization of single use systems

• Reduce cost: Robotic aseptic

Improve supply capacity: DCM

• Bioinformatics: NGS, Neoantigens

Bacteriophages

Scientific advices (n=5)

Support to ITF meetings (n=33)

- Process automation
- CM for biologics
- Decentralised Manufacturing
- Artificial Intelligence (diverse applications)
- RNA writing technology
- 3D bioprinting
- iPSCs
- Drug device

### QIG: key entry point for advanced manufacturing

- Decentralised manufacturing (DCM)
- Automated cell manufacturing
- Digital twins
- Modelling DSP Control strategy
- Continuous Manufacturing: Formulation
- High Tech Facility
- 3-D printing
- Novel technology for virus detection
- Site visits (n=3)

- 1:1 meetings with
- **Developers**

(n=17)

**Guidance**Q&A on use of X-ray sterilisation processes for Single Use Systems- **published** 

- Considerations on process models (Draft)
- Reflections on DCM
- AI reflection paper contrib.
- 3-D Printing (draft)

### Product support by QIG



#### **Direct Contact**

- Technology or product focused
- QIG expert assigned

#### **Scientific Advice**

- QIG expert primary assessor
- technology or product focused
- QIG Input into inspection

#### **Initial MA application**

- QIG expert input as part of assessment team
- QIG Input into inspection

# Variation/line extensions

QIG expert input into review & inspection



### **Product and Technology support across lifecycle**



#### **Entry point to QIG**

Expert advice (CMC/Inspection) No formal assessment



#### **Assessment activities**

assigned QIG expert for primary assessment / peer review



Challenges & solutions gaps



1 - to - 1 Meetings (QIG + Applicant/Sponsor)

Support to specific Product/technology assessment



Knowledge Assessment outcomes

Guidance International convergence Training



### International collaboration: FDA, Swiss Medic, PMDA & ICMRA

#### **Knowledge sharing**

- Bi-monthly meetings
- Attend & Share learnings from workshops, company meetings
- Staff/ expert exchanges

#### **Product specific advices / assessments**

- Consultative / parallel scientific advices /collaborative assessments leading to harmonised outcomes (where possible)
- Joint (hybrid) site visits / inspections

### **Guidance development**

- Exchanging priorities, topics of common interest
- · Aligned or joined guidance/Q&As, joint ICH proposals



EMA is happy to welcome FDA colleagues to exchange mutual experience and current thinking on scientific and regulatory aspects of advanced manufacturing.

The goal is to explore avenues for closer collaboration and support ir ...see more



## Acknowledgements



### **QIG** members

Marcel Hoefnagel (QIG chair, Bio, NL)

Leticia Martinez-Peyrat (Chem, FR)

Christina Meissner (GMP INS, AT)

Silke Schüle (ATMP, DE)

Barbara Stubbe (GMP INS, BE)

Rene Thürmer (Chem/Bio, DE)

Marcos Timon (Bio/ATMP, ES)

Ciara Turley (GMP INS, IR)

### **EMA Team**

Dolores Hernan (QIG secretary, Qual)

Miguel Rodriguez (QIG support, GMP)

Giampiero Lorenti (GMP INS, GMP)

Robert Bream (Qual)

Veronika Jekerle (Qual)

Andrei Spinei (GMP)

Roberto Conocchia (GMP)

Peter Twomey (ISP)

Evdokia Korakianiti (H-QS Dpt)

QIG contact: QIG@ema.europa.eu